Bicycle Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bicycle Therapeutics's earnings have been declining at an average annual rate of -39%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 20.5% per year.
Key information
-39.0%
Earnings growth rate
56.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 20.5% |
Return on equity | -48.7% |
Net Margin | -669.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year
Jan 19Bicycle Therapeutics gives out pipeline update, shares rise
Jan 14What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?
Dec 15Bicycle Therapeutics settles IP dispute with Pepscan
Nov 30Revenue & Expenses BreakdownBeta
How Bicycle Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 27 | -181 | 60 | 0 |
30 Sep 23 | 25 | -162 | 59 | 0 |
30 Jun 23 | 23 | -140 | 52 | 0 |
31 Mar 23 | 15 | -124 | 48 | 0 |
31 Dec 22 | 14 | -113 | 50 | 0 |
30 Sep 22 | 15 | -101 | 50 | 0 |
30 Jun 22 | 16 | -87 | 48 | 0 |
31 Mar 22 | 14 | -78 | 42 | 0 |
31 Dec 21 | 12 | -67 | 32 | 0 |
30 Sep 21 | 12 | -66 | 35 | 0 |
30 Jun 21 | 11 | -62 | 34 | 0 |
31 Mar 21 | 11 | -56 | 32 | 0 |
31 Dec 20 | 10 | -51 | 29 | 0 |
30 Sep 20 | 12 | -38 | 22 | 0 |
30 Jun 20 | 9 | -37 | 19 | 0 |
31 Mar 20 | 9 | -35 | 16 | 0 |
31 Dec 19 | 14 | -31 | 15 | 0 |
30 Sep 19 | 10 | -33 | 13 | 0 |
30 Jun 19 | 11 | -31 | 11 | 0 |
31 Mar 19 | 11 | -26 | 10 | 0 |
31 Dec 18 | 7 | -22 | 8 | 0 |
30 Sep 18 | 7 | -21 | 9 | 0 |
31 Dec 17 | 2 | -16 | 6 | 0 |
Quality Earnings: BCYC is currently unprofitable.
Growing Profit Margin: BCYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BCYC is unprofitable, and losses have increased over the past 5 years at a rate of 39% per year.
Accelerating Growth: Unable to compare BCYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: BCYC has a negative Return on Equity (-48.71%), as it is currently unprofitable.